机译:Ibrutinib作为同种异体HCT慢性淋巴细胞白血病后的救生疗法
Ctr Leon Berard Hematol Dept Lyon France;
Heidelberg Univ Internal Med 5 Heidelberg Germany;
Ctr Leon Berard Hematol Dept Lyon France;
EBMT Data Off Leiden Netherlands;
EBMT Data Off Leiden Netherlands;
EBMT EBMT Lymphoma Working Party Paris France;
Univ Hosp Cologne Dept Internal Med 1 Cologne Germany;
Nottingham Univ Hosp NHS Trust Dept Clin Haematol Nottingham England;
Univ Klinikum Goettingen Dept Hematol &
Oncol Gottingen Germany;
Univ Med Greifswald Dept Hematol Greifswald Germany;
Univ Med Ctr Dept Internal Med Hematol Maastricht Netherlands;
Univ Milan Fdn IRCCS Ist Nazl Tumori Milano Hematol Div Milan Italy;
Brescia Univ Dept Clin &
Expt Sci Unit Blood Dis &
Stem Cell Transplantat ASST Spedali Civili;
Univ Hosp Dept Hematol Basel Switzerland;
Univ Hosp Leuven Dept Hematol Leuven Belgium;
Eberhard Karls Univ Tuebingen Dept Hematol Tubingen Germany;
Radboud Univ Nijmegen Dept Hematol Med Ctr Nijmegen Netherlands;
Erasmus MC Canc Inst Dept Hematol Rotterdam Netherlands;
St James Hosp Hope Directorate Dublin Ireland;
Clin Hosp Ctr Zagreb Dept Hematol Zagreb Croatia;
Martin Luther Univ Halle Wittenberg Dept Hematol Halle Germany;
Barts Hlth NHS Trust Dept Haematooncol St Bartholomews Hosp London England;
Univ Hosp Eppendorf Hamburg Germany;
Univ Hosp Dresden Dept Hematol Dresden Germany;
机译:Ibrutinib作为同种异体HCT慢性淋巴细胞白血病后的救生疗法
机译:依鲁替尼在同种异体HCT后复发的慢性淋巴细胞性白血病患者中的疗效和耐受性
机译:在慢性淋巴细胞性白血病(CLL)中,同种异体造血细胞移植(HCT)比化学疗法(CT)拥有更好的下一次治疗(TTNT)时间
机译:使用机器学习生存率和分类方法预测慢性淋巴细胞白血病首次治疗的时间
机译:激酶靶向疗法在慢性淋巴细胞性白血病中:获得性依鲁替尼耐药性的机制和OSU-T315的临床前开发。
机译:依鲁替尼在同种异体HCT后复发的慢性淋巴细胞性白血病患者中的疗效和耐受性
机译:慢性淋巴细胞性白血病(CLL)的同种异体造血细胞移植(HCT)的结果:清髓性(MA)VS的影响。降低强度调理(RIC)方案,以及基于全身照射(TBI)的MA与基于化学疗法(CT)的MA调理的影响